Anti-Human IL-12/23 (Ustekinumab) - 1.0 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

IL-12 and IL-23 play a role in the differentiation and proliferation of type 1 T-helper cells (Th1)1. IL-12 stimulates IFN-γ and TNF-α production via Th1 differentiation, whereas IL-23 causesactivation of IL-17-producing T cells2. IL-12 and IL-23 are members of the IL-12 cytokinefamily3. Members of the IL-12 family form soluble heterodimers consisting of α and β subunits.IL-12 and IL-23 both have a p40 subunit, and either p40 can bind to the IL-12 β1 receptor1, 2, 4.IL-23 consists of IL-12p40 and IL-23p193. IL-12 consists of IL-12p40 and IL-12p35.IL-23 is associated with various autoimmune inflammatory diseases and is particularly highlyexpressed in psoriasis skin lesions1, 2. Furthermore, IL-23 is suspected to play a role intumorigenesis3. Anti-IL12/23 p40 antibodies antagonize key pathways in inflammatoryautoimmune diseases, such as arthritis and colitis1, 2.Ustekinumab was developed from transgenic mice as an antibody against the p40 subunits of IL-12/231, 2. Ustekinumab binds with high affinity and specificity to p40, preventing interaction withthe IL-12 β1 receptor found on natural killer cells or T cells and blocking downstream signaling, differentiation, and cytokine production1, 2, 4. Additionally, ustekinumab inhibits up-regulation ofcutaneous lymphocyte antigen, IL-2, IL-2Rα, and IL-12R as well as secretion of IFN-γ, TNF-α, and IL-17A.Ustekinumab is used in clinical settings to treat plaque psoriasis, Crohn’s disease, and ulcerativecolitis.

≥ 5.0 mg/ml

IL-12 is produced by dendritic cells, macrophages, neutrophils, and humanB-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages, ormonocytes. Both are produced by activated antigen-presenting cells.